Vehicle seat
    2.
    发明授权

    公开(公告)号:US09937837B2

    公开(公告)日:2018-04-10

    申请号:US15059900

    申请日:2016-03-03

    IPC分类号: B60N2/68 B60N2/64 A47C5/04

    摘要: A vehicle seat includes a seat frame. The seat frame has a hollow deformable portion that is bent, and linear recessed portions formed by partially recessing an inner side of the deformable portion. The deformable portion has a linear separation portion formed in a projecting manner relative to the recessed portions and extending on the inner side of the deformable portion. A plurality of recessed portions is formed on each of one side and the other side of the separation portion so as to sandwich the separation portion, and placed independently from each other such that adjacent recessed portions are not connected to each other.

    Polysulfone-based blood treatment membrane and method of producing the same
    3.
    发明授权
    Polysulfone-based blood treatment membrane and method of producing the same 有权
    聚砜类血液处理膜及其制造方法

    公开(公告)号:US08220642B2

    公开(公告)日:2012-07-17

    申请号:US12601543

    申请日:2008-05-26

    IPC分类号: B01D69/00 B01D69/02 B01D67/00

    摘要: A polysulfone-based blood treatment membrane that exhibits excellent antioxidant properties, excellent long-term storage stability, and a practical strength, and ensures high productivity, a polysulfone-based blood treatment membrane that exhibits excellent antioxidant properties and long-term storage stability, rarely allows endotoxins to enter a treatment liquid, exhibits a practical strength, and ensures high productivity, and a method of producing the same. A polysulfone-based blood treatment membrane includes a polysulfone-based resin, a hydrophilic polymer, and a lipophilic antioxidant, the membrane containing the lipophilic antioxidant in an amount of 30 to 76 mg per gram of the membrane, and the total amount of the lipophilic antioxidant present on the surface of the membrane being 4 to 25 mg per gram of the membrane. Another polysulfone-based blood treatment membrane contains a lipophilic antioxidant in an amount of 30 to 76 mg per gram of the membrane, wherein the inner surface of the membrane has a TOF-SIMS normalized peak intensity of the lipophilic antioxidant of 1.8.times.10.sup.-4 or more, and the outer surface of the membrane has a TOF-SIMS normalized peak intensity of the lipophilic antioxidant of 2.4.times.10.sup.-4 or more. A method of producing a polysulfone-based blood treatment membrane that includes a polysulfone-based resin, a hydrophilic polymer, and a lipophilic antioxidant includes producing a membrane intermediate that contains the lipophilic antioxidant in an amount of 30 to 76 mg per gram of the membrane intermediate, and heating the membrane intermediate at 100 to 180.degree. C. for 0.1 to 360 minutes in a dry state.

    摘要翻译: 一种聚砜系血液处理膜,其表现出优异的抗氧化性能,优异的长期保存稳定性和实用强度,并且确保高生产率,表现出优异的抗氧化性能和长期保存稳定性的聚砜系血液处理膜,很少 允许内毒素进入处理液,具有实用的强度,并且确保高生产率及其制备方法。 基于聚砜的血液处理膜包括聚砜系树脂,亲水性聚合物和亲脂性抗氧化剂,每克膜含有30〜76mg的亲脂性抗氧化剂的膜和亲脂性的总量 存在于膜表面的抗氧化剂每克膜为4至25mg。

    Black-to-color shifting security element
    5.
    发明授权
    Black-to-color shifting security element 有权
    黑色到彩色安全元素

    公开(公告)号:US08147932B2

    公开(公告)日:2012-04-03

    申请号:US11912348

    申请日:2006-04-05

    IPC分类号: B44F1/10 B41M5/00 G03G7/00

    摘要: The invention discloses a security element for a banknote, a document of value, right or identity, a ticket, a label, a branded good identifier, or a tax banderole. The element comprises a combination of a coating containing at least one optically variable pigment having a substantial viewing-angle dependent color variation, with at least one selective spectral absorbing material, which blocks out visible spectral components reflected by the optically variable pigment at orthogonal incidence. The security element appears black when viewed at orthogonal angle, and colored when viewed at grazing angle.

    摘要翻译: 本发明公开了一种用于钞票,价值文件,权利或身份证件,票证,标签,品牌商品标识符或税吏的安全元件。 该元件包括含有至少一种具有大致视角决定颜色变化的光学可变颜料的涂层与至少一种选择性光谱吸收材料的组合,其阻挡由光学可变颜料在正交入射下反射的可见光谱分量。 当以正交角度观察时,安全元件看起来为黑色,并且在掠角观察时显示为彩色。

    2-morpholino-4-pyrimidone compound
    8.
    发明授权
    2-morpholino-4-pyrimidone compound 有权
    2-吗啉代-4-嘧啶酮化合物

    公开(公告)号:US08106045B2

    公开(公告)日:2012-01-31

    申请号:US11573476

    申请日:2005-09-09

    CPC分类号: C07D413/14

    摘要: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C1-C12 alkyl; R2 represents a hydrogen atom, or the like; R′ represents a C1-C6 alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C1-C6 alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

    摘要翻译: 由式(I)表示的化合物,其光学活性异构体或其药学上可接受的盐:其中X表示CH或N; 表示C1-C12烷基; R2表示氢原子等; R'表示C1-C6烷基等; q表示0或1〜7的整数, Y表示C1-C6烷基等; p表示0或1〜5的整数。 R表示2,3-二氢吲哚基等,其用于预防和/或治疗由tau蛋白激酶1多动症如神经变性疾病(例如阿尔茨海默病)引起的疾病。

    Method for forming organ
    9.
    发明授权
    Method for forming organ 失效
    器官形成方法

    公开(公告)号:US08105833B2

    公开(公告)日:2012-01-31

    申请号:US12535576

    申请日:2009-08-04

    IPC分类号: C12N5/00 C12N5/07 C12N5/071

    摘要: A method for forming an organ and/or tissue from undifferentiated cells derived from a vertebrate animal in vitro, which comprises the step of culturing the undifferentiated cells derived from a vertebrate animal in the presence of a retinoic acid X receptor ligand (e.g., a retinoic acid X receptor agonist or antagonist), and a method for forming a pancreas from undifferentiated cells derived from a vertebrate animal in vitro or a method for forming a tissue having morphology and function of a pancreas from undifferentiated cells derived from a vertebrate in vitro, which comprises the step of culturing the undifferentiated cells derived from a vertebrate animal in the presence of a retinoic acid receptor ligand, together with activin, that does not substantially bind to the retinoic acid receptor subtype γ.

    摘要翻译: 一种用于从体外衍生自脊椎动物的未分化细胞形成器官和/或组织的方法,其包括在视黄酸X受体配体(例如视黄酸)存在下培养源自脊椎动物的未分化细胞的步骤 酸X受体激动剂或拮抗剂)以及从体外衍生自脊椎动物的未分化细胞形成胰腺的方法或用于从体外衍生自脊椎动物的未分化细胞形成具有胰腺形态和功能的组织的方法,其中 包括在视黄酸受体配体存在下培养源自脊椎动物的未分化细胞与活化素一起基本上不结合视黄酸受体亚型γ的步骤。

    Method for manufacturing an anisotropic conductive adhesive sheet
    10.
    发明授权
    Method for manufacturing an anisotropic conductive adhesive sheet 有权
    各向异性导电粘合片的制造方法

    公开(公告)号:US08084083B2

    公开(公告)日:2011-12-27

    申请号:US13008537

    申请日:2011-01-18

    IPC分类号: B05D1/12

    摘要: A method for manufacturing an anisotropic conductive adhesive sheet is disclosed. The sheet comprises at least a curing agent, a curable insulating resin, and conductive particles. The method comprises providing an adhesive layer on a biaxially stretchable film to form a laminate, densely packing conductive particles having an average particle size of 1 to 8 μm on the laminate to form a conductive particle-attached film, biaxially stretching and holding the conductive particle-attached film so that the average particle distance between adjacent conductive particles is at least one to five times or less the average particle size of the conductive particles and not greater than 20 μm. The conductive particles are transferred to an adhesive sheet containing at least a curing agent and a curable insulating resin and having a thickness of at least 1.5 times the average particle distance between the conductive particles but not greater than 40 μm.

    摘要翻译: 公开了一种制造各向异性导电粘合片的方法。 该片材至少包含固化剂,可固化绝缘树脂和导电颗粒。 该方法包括在双轴拉伸膜上设置粘合剂层以形成层压体,在层压板上密集填充平均粒度为1至8μm的导电颗粒以形成导电颗粒附着膜,双轴拉伸并保持导电颗粒 使得相邻导电粒子之间的平均粒子距离为导电粒子的平均粒径的至少一倍以上且不大于20μm。 将导电性粒子转移到至少含有固化剂和固化性绝缘性树脂的粘合片,其厚度为导电性粒子之间的平均粒子距离的至少1.5倍,但为40μm以下。